Buprenorphine induced opioid withdrawal syndrome relieved by adjunctive Magnesium: A clinical trial.

Introduction: Precipitated opioid withdrawal syndrome (OWS) is a severe and intolerable situation that may occur by a pharmaceutical agent. Reactivation of inhibited N-methyl-d-aspartate (NMDA) receptor in person with prolonged opioid use can led to severe OWS. We conducted a double-blind, randomized clinical trial to assess the effect of magnesium sulfate (MGSO) as an NMDA receptor antagonist on OWS.